HP
RXDX

HealthInvest Partners’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

HealthInvest Partners’s Portfolio RXDX Stock Details RXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$13.4K Buy
+122
New +$7.91K 0.03% 35

Other funds holding RXDX

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
7IH
72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

HealthInvest Partners's RXDX Position: Q4 2022 in Review

HealthInvest Partners opened a new position in Prometheus Biosciences, Inc. Common Stock (RXDX) in Q4 2022: 122 shares worth $13.4K. The stake represents 0.03% of the portfolio and ranks #35 among its holdings.

221 funds tracked by Wall St. Rank hold RXDX as of Q4 2022.

  • HealthInvest Partners held 122 shares of Prometheus Biosciences, Inc. Common Stock worth $13.4K as of Q4 2022.
  • Prometheus Biosciences, Inc. Common Stock was a new HealthInvest Partners position in Q4 2022.
  • Prometheus Biosciences, Inc. Common Stock made up 0.03% of HealthInvest Partners's portfolio in Q4 2022, its #35 holding.
  • 221 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q4 2022.

Based on HealthInvest Partners's 13F filing for Q4 2022, filed 14 Feb 2023.